Elevations in C-reactive Protein and Endothelin-1 System Activity in Humans
Overview
Biology
Physiology
Authors
Affiliations
Aims: C-reactive protein (CRP) is an inflammatory cytokine that has been shown to be an independent predictor of future atherothrombotic events. Hyperactivity of endothelin-1 (ET-1), a potent vasoconstrictor peptide produced by the endothelium, is linked with cardiovascular disease development and progression. ET-1 is sensitive to inflammatory stimuli, though the influence of CRP on ET-1 system activity is unknown. We tested the hypothesis that ET-1-mediated vasoconstrictor tone is enhanced in adults with elevated plasma CRP concentrations.
Materials And Methods: Sixty non-obese adults (43-70years) were studied: 20 with hsCRP<1.0mg/L (low CRP; 0.5±0.1mg/L); 20 with hsCRP 1.0-3.0mg/L (moderate CRP; 2.0±0.1mg/L); and 20 with hsCRP>3.0mg/L (high CRP; 6.3±0.5mg/L). Forearm blood flow (FBF; plethysmography) was determined in response to intra-arterial infusions of ET-1 (5pmol/min for 20min) and selective ETA receptor blockade (BQ-123, 100nmol/min for 60min).
Key Findings: In response to ET-1, FBF decreased ~10% in the low (-10.0±2.3%), moderate (-10.7±4.0%), and high (-6.6±5.2%) CRP groups, with no significant differences between groups. Additionally, all groups demonstrated a marginal, though significant (~10%), vasodilator response to BQ-123; however, there were no differences in the FBF response to BQ-123 across CRP groups. There were no significant correlations between plasma CRP concentrations and peak FBF response to either ET-1 or BQ-123.
Significance: These results indicate that ET-1 system activity is not influenced by elevations in CRP. Enhanced ET-1 system activity may not be involved in the increased cardiovascular disease risk associated with elevations in plasma CRP concentrations.
Gouaref I, Otmane A, Makrelouf M, Abderrhmane S, Haddam A, Koceir E Int J Mol Sci. 2024; 25(17).
PMID: 39273236 PMC: 11395650. DOI: 10.3390/ijms25179288.
C-Reactive Protein in Atherosclerosis-More than a Biomarker, but not Just a Culprit.
Kirkgoz K Rev Cardiovasc Med. 2024; 24(10):297.
PMID: 39077585 PMC: 11262456. DOI: 10.31083/j.rcm2410297.
Dabek J, Piotrkowicz J, Glogowska-Ligus J, Domagalska-Szopa M, Szopa A, Schreiber L Int J Environ Res Public Health. 2022; 19(12).
PMID: 35742539 PMC: 9224255. DOI: 10.3390/ijerph19127289.
Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going.
Haryono A, Ramadhiani R, Ryanto G, Emoto N Biology (Basel). 2022; 11(5).
PMID: 35625487 PMC: 9138590. DOI: 10.3390/biology11050759.
Li Y, Sheu W, Lee W, Wang J, Fu C, Liang K Sci Rep. 2018; 8(1):7378.
PMID: 29743680 PMC: 5943599. DOI: 10.1038/s41598-018-25763-4.